Advertisement
INSM vs JAZZ
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Hold and JAZZ is a Hold.
Momentum Indicator for INSM turns positive, indicating new upward trend
INSM saw its Momentum Indicator move above the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 74 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for INSM just turned positive on October 27, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in 40 of 52 cases over the following month. The odds of a continued upward trend are 77%.
Following a +16.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 202 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for INSM moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 25 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 59 cases where INSM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
The 10-day moving average for INSM crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
INSM broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INSM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (30.109) is normal, around the industry mean (3.051). P/E Ratio (-25.350) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
JAZZ's RSI Oscillator recovers from oversold territory
The RSI Oscillator for JAZZ moved out of oversold territory on October 29, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 19 of the 26 cases the stock moved higher. This puts the odds of a move higher at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on JAZZ as a result. In 61 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for JAZZ just turned positive on October 29, 2026. Looking at past instances where JAZZ's MACD turned positive, the stock continued to rise in 31 of 49 cases over the following month. The odds of a continued upward trend are 63%.
Following a +5.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in 176 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
JAZZ broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JAZZ entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.106) is normal, around the industry mean (3.051). P/E Ratio (15.105) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
INSM | JAZZ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 85 Overvalued | |
PROFIT vs RISK RATING 1..100 | 60 | 35 | |
SMR RATING 1..100 | 98 | 44 | |
PRICE GROWTH RATING 1..100 | 60 | 57 | |
P/E GROWTH RATING 1..100 | 45 | 97 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INSM's Valuation (79) in the Biotechnology industry is in the same range as JAZZ (85) in the Pharmaceuticals Other industry. This means that INSM’s stock grew similarly to JAZZ’s over the last 12 months.
JAZZ's Profit vs Risk Rating (35) in the Pharmaceuticals Other industry is in the same range as INSM (60) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to INSM’s over the last 12 months.
JAZZ's SMR Rating (44) in the Pharmaceuticals Other industry is somewhat better than the same rating for INSM (98) in the Biotechnology industry. This means that JAZZ’s stock grew somewhat faster than INSM’s over the last 12 months.
JAZZ's Price Growth Rating (57) in the Pharmaceuticals Other industry is in the same range as INSM (60) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to INSM’s over the last 12 months.
INSM's P/E Growth Rating (45) in the Biotechnology industry is somewhat better than the same rating for JAZZ (97) in the Pharmaceuticals Other industry. This means that INSM’s stock grew somewhat faster than JAZZ’s over the last 12 months.
| INSM | JAZZ | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 73% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 59% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 71% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 58% |
| Advances ODDS (%) | 5 days ago 69% | 5 days ago 60% |
| Declines ODDS (%) | 1 day ago 76% | 9 days ago 55% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 0 FA rating(s) are green while JAZZ’s FA Score has 0 green FA rating(s).
- INSM’s FA Score: 0 green, 5 red.
- JAZZ’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 3 TA indicator(s) are bullish while JAZZ’s TA Score has 4 bullish TA indicator(s).
- INSM’s TA Score: 3 bullish, 6 bearish.
- JAZZ’s TA Score: 4 bullish, 4 bearish.
Price Growth
INSM (@Biotechnology) experienced а +9.98% price change this week, while JAZZ (@Biotechnology) price change was +11.10% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.
Reported Earning Dates
INSM is expected to report earnings on Feb 25, 2027.
JAZZ is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (-2.09% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement